Metraipolis › archive › dc_92bf04d058ab

Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts — Europe PMC PMID:42488471

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42488471
DOI
10.1002/hem3.70438
License (as archived)
solo-consultazione
Archived
2026-10-17T22:56:57.834Z
SHA-256 of the archived text
2dff3af44e90b3f13b36fa11d4704a0ad94968f6c759731d373cc1a44f2321bc
Stable URL of this page
https://metraipolis.com/documento/dc_92bf04d058ab

How to cite

Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts — Europe PMC PMID:42488471 — Europe PMC (en), https://europepmc.org/article/MED/42488471 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_92bf04d058ab (Metraipolis archive dc_92bf04d058ab, sha256 2dff3af44e90b3f13b36fa11d4704a0ad94968f6c759731d373cc1a44f2321bc)
BibTeX
@misc{dc92bf04d058ab,
  title = {Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts — Europe PMC PMID:42488471},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42488471},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_92bf04d058ab; sha256 2dff3af44e90b3f13b36fa11d4704a0ad94968f6c759731d373cc1a44f2321bc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42488471. Agents can read the archived copy with the MCP tool read_document.